FindTrial
Sign In

Alternate-Day Buprenorphine Administration. Phase IV - 5

Alternate-Day Buprenorphine Administration. Phase IV

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000223
Enrollment
0
Registered
1999-09-21
Start date
1993-06-30
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders

Brief summary

The purpose of this study is to determine if three times a subject's daily maintenance dose will hold for 72 hours without changes in agonist and antagonist effects.

Interventions

DRUGBuprenorphine

Sponsors

University of Vermont
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 49 Years
Healthy volunteers
No

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frame
Drug use—
Opioid withdrawal—
Opioid agonist effects—
Dose identification—
Pupil diameter—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026